Phase II
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 28, 2020.
With emergency approval, the Oxford University researchers believe they could have a few million doses of the vaccine available by September if it is proven effective.
About 70% of AD patients have symptoms of agitation, which is marked by emotional distress, aggressive behaviors, disruptive irritability and loss of inhibition.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 27, 2020.
Despite the domination of the news cycle by the COVID-19 pandemic, quite a number of biopharma companies reported on non-COVID-19 clinical trials last week, although there remains plenty of ongoing trial news related to the pandemic. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 24, 2020.
The company said the treatment significantly reduced disease activity as measured by magnetic resonance imaging.
On March 16, Moderna and the National Institute of Allergy and Infectious Disease (NIAID) began dosing patients with mRNA-1273, its vaccine candidate against COVID-19. The second round of dosing in healthy Seattle volunteers has now begun.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 23, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 22, 2020.
PRESS RELEASES